research use only
Cat.No.S8665
| Molecular Weight | 525.59 | Formula | C27H33F2N7O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1936422-33-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CNC(=O)N1CCC2=C(C1)C(=N[N]2C3CCOCC3)N4CCCC5=C4C=C(C(F)F)C(=C5)C6=C[N](C)N=C6 | ||
|
In vitro |
DMSO
: 125 mg/mL
(237.82 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
CBP
(in TR-FRET assay) 0.94 nM
BRET
(Cell-free assay) 6.2 nM
BRD4(1)
(Cell-free assay) 5100 nM
|
|---|---|
| In vitro |
In vitro studies show that GNE-781 reduces FOXP3 (forkhead box P3) transcript levels with a less optimal chemical probe, suggesting that inhibition of the CBP bromodomain may provide a novel small molecule therapeutic approach for cancer immunotherapy. This compound decreases the generation of iTregs in vitro without affecting cell viability. |
| In vivo |
GNE-781, a highly potent and selective CBP inhibitor that is efficacious in a MOLM-16 AML xenograft model. In vivo, this compound modulates MYC expression that corresponds with antitumor activity in an AML tumour model. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.